KRM Ayurveda Stocks to List Today. GMP indicates a healthy premium on debut

KRM Ayurveda’s shares were trading at a gray market premium of around 17% before the company’s listing on the NSE SME platform, indicating positive sentiment among casual market participants despite mixed views on the valuation. Based on the upper end of the price range of Rs 135 per share, the GMP of around Rs 23 suggests an implied listing price of around Rs 158, if sentiment holds up till debut.The Rs 77 crore IPO, which was all new, saw very strong demand across all investor categories during the subscription period. The issue was subscribed a total of 74.27 times, with non-institutional investors subscribing 135.37 times, qualified institutional buyers subscribing 63.31 times and retail investors subscribing 54.21 times. The strong response was seen as a key factor supporting the gray market premium prior to the listing.

KRM Ayurveda offered shares in a price range of Rs 128 to Rs 135, with the issue priced at the higher end. At the issue price, the company is valued at around Rs 287 crore. The IPO consisted of 57.4 lakh shares, of which 51.66 lakh shares were offered to the public after taking into account the market maker portion.

The company raised Rs 20.82 crore from anchor investors ahead of the issue, which helped set the tone for subscription. The issuance was managed by NEXGEN Financial Solutions, with Skyline Financial Services acting as registrar.

KRM Ayurveda operates a network of hospitals and clinics that focus on Ayurvedic healthcare, along with the production and sale of Ayurvedic and herbal products. As of December 31, 2025, the company operated six hospitals and five clinics across India and had a total of 443 employees. Its activities also include telemedicine consultations and product sales, including in overseas markets.

Financially, the company reported profit after tax of Rs 12.1 crore for FY25 and Rs 8.14 crore for the six months ended September 2025. EBITDA margins stood at 26.54%, while return on equity stood at 21.84% as of September 2025.

It is proposed that the proceeds from the IPO will be used for expansion of telemedicine facilities, technology upgrades, loan repayment, working capital needs and general corporate purposes.